{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"groups":[{"description":"Gemcitabine 900 mg/m2 IV days 1 and 8 Docetaxel 75 mg/m2 IV day 8 GCSF 5 micrograms/kg days 9-15 or pegfilgrastim 6 mg day 9 or 10 Every 21 days for 4 cycles CT/MRI imaging to confirm disease-free Doxorubicin 60 mg/m2 IV every 21 days for 4 cycles","id":"OG000","title":"Regimen 1"},{"description":"Observation","id":"OG001","title":"Regimen II"}],"paramType":"NUMBER","populationDescription":"eligible and randomized patients","reportingStatus":"POSTED","timeFrame":"Approximately 4 years","title":"Incidence of Grade 3 or Higher Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0","type":"SECONDARY","unitOfMeasure":"participants"}